Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1892MR)

This product GTTS-WQ1892MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Cervical Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ1892MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3896MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BCD-100
GTTS-WQ10983MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MCDS0593A
GTTS-WQ9071MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMC-A12
GTTS-WQ7224MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ12924MR IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PankoMab
GTTS-WQ917MR IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-221
GTTS-WQ342MR IVTScrip™ mRNA-Anti-CD27, 1F5(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 1F5
GTTS-WQ3443MR IVTScrip™ mRNA-Anti-S, AZD8895(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AZD8895
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW